SARS‐CoV‐2 triggers complement activation through interactions with heparan sulfate

• Published in: Clinical & translational immunology Vol. 11; no. 8; pp. e1413 - n/a
• Main Authors: Lo, Martin W, Amarilla, Alberto A, Lee, John D, Albornoz, Eduardo A, Modhiran, Naphak, Clark, Richard J, Ferro, Vito, Chhabra, Mohit, Khromykh, Alexander A, Watterson, Daniel, Woodruff, Trent M
• Format: Journal Article
• Language: English
• Published: Milton, Queensland John Wiley & Sons, Inc 2022; John Wiley and Sons Inc; Wiley
• Subjects: Alternative pathway; CD11b antigen; Cell surface; complement; Complement activation; Complement component C3; Complement component C5a; Complement receptors; coronavirus; Coronaviruses; COVID-19; Drug dosages; Flow cytometry; Heparan sulfate; Infections; Inoculation; Investigations; Lectins; leukocyte activation; Leukocytes (granulocytic); Monocytes; Neutrophils; Plasma; Proteins; SARS‐CoV‐2; Severe acute respiratory syndrome coronavirus 2; Short Communication; Signal transduction

Objectives To determine whether SARS‐CoV‐2 can trigger complement activation, the pathways that are involved and the functional significance of the resultant effect. Methods SARS‐CoV‐2 was inoculated into a human lepirudin‐anticoagulated whole blood model, which contains a full repertoire of complem...